PIII vs. XGN, SERA, DCGO, EUDA, QIPT, CORBF, BNR, ATPC, BDSX, and BMGL
Should you be buying P3 Health Partners stock or one of its competitors? The main competitors of P3 Health Partners include Exagen (XGN), Sera Prognostics (SERA), DocGo (DCGO), EUDA Health (EUDA), Quipt Home Medical (QIPT), Global Cord Blood (CORBF), Burning Rock Biotech (BNR), Agape ATP (ATPC), Biodesix (BDSX), and Basel Medical Group (BMGL). These companies are all part of the "healthcare" industry.
P3 Health Partners vs. Its Competitors
Exagen (NASDAQ:XGN) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.
75.3% of Exagen shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 12.6% of Exagen shares are owned by company insiders. Comparatively, 17.8% of P3 Health Partners shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Exagen's average media sentiment score of 0.95 beat P3 Health Partners' score of 0.83 indicating that Exagen is being referred to more favorably in the media.
Exagen has higher earnings, but lower revenue than P3 Health Partners. Exagen is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.
Exagen presently has a consensus target price of $12.60, indicating a potential upside of 9.19%. P3 Health Partners has a consensus target price of $16.25, indicating a potential upside of 83.93%. Given P3 Health Partners' higher possible upside, analysts clearly believe P3 Health Partners is more favorable than Exagen.
Exagen has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, P3 Health Partners has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
P3 Health Partners has a net margin of -9.99% compared to Exagen's net margin of -28.85%. Exagen's return on equity of -130.38% beat P3 Health Partners' return on equity.
Summary
Exagen beats P3 Health Partners on 9 of the 15 factors compared between the two stocks.
Get P3 Health Partners News Delivered to You Automatically
Sign up to receive the latest news and ratings for PIII and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PIII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
P3 Health Partners Competitors List
Related Companies and Tools
This page (NASDAQ:PIII) was last updated on 10/17/2025 by MarketBeat.com Staff
